Gofar Stock(SH:600538) Chang Jiang Shang Bao·2026-02-24 23:43Core Viewpoint - Guofang Co., Ltd. (600538.SH) has reported a continuous loss for three consecutive years, raising significant regulatory concerns regarding its financial performance and future outlook [1][2][3]. Financial Performance - For 2025, Guofang expects to achieve approximately 330 million yuan in revenue, with a net loss attributable to shareholders of around 85 million yuan, and a net loss after excluding non-recurring items of about 85.5 million yuan, reflecting a reduction in losses compared to the previous year [1][3]. - The company has experienced revenue declines of 3.2% year-on-year, with a gross margin of 22.6%, down 3.03 percentage points from the previous year [1][3]. - Historical performance shows fluctuations, with revenues of 460 million yuan, 369 million yuan, and 340 million yuan from 2022 to 2024, alongside net profits of 34.84 million yuan, -82.31 million yuan, and -93.85 million yuan respectively [2][3]. Business Segments - The main business segments include pharmaceutical manufacturing, pharmaceutical distribution, and judicial IVD, generating revenues of 191 million yuan, 27.14 million yuan, and 107 million yuan respectively, with year-on-year changes of 4.43%, -23.44%, and -10% [4]. - The gross margins for these segments are 13.7%, 35.56%, and 36.48%, showing declines in each segment [4]. Impairment of Goodwill - A significant factor affecting Guofang's performance is the impairment of goodwill related to its acquisition of Guangzhou Gaosheng Biotechnology Co., Ltd., which has led to a cumulative impairment provision of 178 million yuan from 2023 to 2025 [5][7]. - The company acquired Gaosheng for 356 million yuan in 2021, which has not met performance expectations, resulting in substantial impairments in 2023 and 2024 [5][6]. - Guofang plans to recognize an additional impairment provision of approximately 62.45 million yuan for 2025, indicating ongoing challenges in achieving projected revenue and profit levels [6][7]. Market Conditions - Increased market competition and a decline in government funding have adversely affected Gaosheng's revenue and profit margins, contributing to the overall financial difficulties faced by Guofang [6][7]. - The company has noted a decrease in orders for its judicial IVD business, which is expected to impact future revenue generation [6].